Garfield Alastair sold 2,007 shares of RHYTHM PHARMACEUTICALS, INC. at $116.11 for −$233k on Aug 13, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Scientific Officer
Chief Scientific Officer
Filed Aug 17, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$233,031.37Shares × reported price
Shares traded
2,007Common Stock
Price per share
$116.11Reported price. Read footnotes for ranges.
% of reported position traded
19.95%This security and ownership context
Holdings after
8,051Direct
Trade date
Aug 13, 2026Sell
Filed
Aug 17, 2026, 5:57 PM ET4-day reporting delay
Accession
0001649904-26-000013Code S · Transaction 1057
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 10,058 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 13, 2026Sell1,556$117.08−$182,170.10Trade 1058
Aug 13, 2026Sell3,400$118.28−$402,166.62Trade 1059
Aug 13, 2026Sell800$119.17−$95,335.04Trade 1060
4 transaction rows in this filing. Joint filers share the same rows.

RYTM price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
RYTM · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −4.7%1w ago −2.9%1d ago +1.9%
Returns since7d −3.5%30d −15%90d180d1y

Footnotes in full

F1: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.67 to $116.62 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $116.72 to $117.66 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $117.73 to $118.71 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $118.73 to $119.52 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.